Se connecter Inscription gratuite

Last updated: 20 June 2022 at 4:10pm EST

David Beier Net Worth




The estimated Net Worth of David W Beier is at least $775 millier dollars as of 3 May 2012. Mr. Beier owns over 55,000 units of Infinity Pharmaceuticals stock worth over $1,812 and over the last 17 years he sold INFI stock worth over $773,400. In addition, he makes $0 as Independent Director at Infinity Pharmaceuticals.

Mr. Beier INFI stock SEC Form 4 insiders trading

David has made over 4 trades of the Infinity Pharmaceuticals stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 55,000 units of INFI stock worth $3,073,950 on 3 May 2012.

The largest trade he's ever made was exercising 57,500 units of Infinity Pharmaceuticals stock on 27 January 2012 worth over $2,793,925. On average, David trades about 4,470 units every 8 days since 2008. As of 3 May 2012 he still owns at least 90,612 units of Infinity Pharmaceuticals stock.

You can see the complete history of Mr. Beier stock trades at the bottom of the page.





David Beier biography

David William Beier J.D. serves as Independent Director of the Company. Mr. Beier has served as a Managing Director of Bay City Capital, a life sciences investment firm, since February 2013. Further, he was on the senior management teams of Amgen Inc. from December 2003 to January 2013, where he most recently held the position of senior vice president, global policy, and Genentech, Inc., a member of the Roche Group, from April 1989 to April 1998, where he most recently held the position of vice president, government affairs. Mr. Beier served in the White House from April 1998 to January 2001 as the Chief Domestic Policy Advisor to Vice President Al Gore during the Clinton Administration. President Clinton appointed him to an Institute of Medicine panel on the Future of Health and Human Services and as an advisor to the President’s Council of Advisors on Science and Technology. Mr. Beier was also formerly a partner in the international law firm Hogan and Hartson, now Hogan Lovells, from April 2001 to December 2003 and was counsel to the U.S. House of Representatives Committee on the Judiciary from April 1979 to April 1989. Since June 2014, Mr. Beier has served as an appointee of then-Governor Brown on the California State Government Organization and the Economy Commission as a Fellow of the Center for Global Enterprise, a position to which he was first appointed by then-Governor Brown, and has been a committee member of the National Academy of Sciences panel on genome editing since 2015. Mr. Beier has served on the board of directors at Arcus Biosciences, a publicly traded biotechnology company, since January 2018; University of California, San Francisco, Benioff Children’s Hospitals since 2014; and the California Life Sciences Association, a life sciences advocacy and business leadership organization, since August 2017.



How old is David Beier?

David Beier is 71, he's been the Independent Director of Infinity Pharmaceuticals since 2018. There are 1 older and 16 younger executives at Infinity Pharmaceuticals. The oldest executive at Infinity Pharmaceuticals Inc. is Anthony Evnin, 79, who is the Independent Director.

What's David Beier's mailing address?

David's mailing address filed with the SEC is C/O INFINITY PHARMACEUTICALS, INC., 1100 MASSACHUSETTS AVENUE, FLOOR 4, CAMBRIDGE, MA, 02138.

Insiders trading at Infinity Pharmaceuticals

Over the last 18 years, insiders at Infinity Pharmaceuticals have traded over $485,846,497 worth of Infinity Pharmaceuticals stock and bought 22,639,120 units worth $175,155,554 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... et Medical Co L.P. Rosebay. On average, Infinity Pharmaceuticals executives and independent directors trade stock every 70 days with the average trade being worth of $14,976. The most recent stock trade was executed by Adelene Q Perkins on 8 September 2023, trading 768,133 units of INFI stock currently worth $15,363.



What does Infinity Pharmaceuticals do?

the mission of infinity pharmaceuticals, inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation. small molecule discovery and development capabilities infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation. strategic alliances building on its strengths in innovative small molecule drug discovery and development, infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline. business and scientific expertise the company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business



What does Infinity Pharmaceuticals's logo look like?

Infinity Pharmaceuticals Inc. logo

Complete history of Mr. Beier stock trades at AMGEN, Infinity Pharmaceuticals et Arcus Biosciences Inc

Date
#
Société
 Initié
Trans.
Transaction
 Actions Prix par action Prix ​​total Actions après Source
3 May 2012 AMGN AMGEN Inc. David W Beier
SVP Global Govt et Corp Affairs
 Exercice d'option 55,000 $55.89 $3,073,950
3 May 2012
90,612 ↗
7 Feb 2012 AMGN AMGEN Inc. David W Beier
SVP Global Govt et Corp Affairs
 Exercice d'option 20,000 $54.44 $1,088,800
7 Feb 2012
51,902 ↗
27 Jan 2012 AMGN AMGEN Inc. David W Beier
SVP Global Govt et Corp Affairs
 Exercice d'option 57,500 $48.59 $2,793,925
27 Jan 2012
89,402 ↗
15 Aug 2011 AMGN AMGEN Inc. David W Beier
SVP Global Govt et Corp Affairs
 Vente 15,000 $51.56 $773,400
15 Aug 2011
31,902 ↗


Infinity Pharmaceuticals executives and stock owners

Infinity Pharmaceuticals executives and other stock owners filed with the SEC include: